Citations

Clear

2358 citation(s) found for "Yu, Long".

Long-term Outcomes of Sequential Hematopoietic Stem Cell Transplantation and Kidney Transplantation: Single-center Experience
Moreira, Carla, Litzow, Mark R. , Russell, Stephen J. , Ansell, Stephen M. , Prieto, Mikel , Dean, Patrick G. , Nyberg, Scott L. , Ters, Mireille El , Amer, Hatem , Cosio, Fernando G., El Ters, Mireille, Russell, Stephen J , Amer, Hatem , Sidiqi, M Hasib , Buadi, Francis K. , Gertz, Morie A. , Dispenzieri, Angela , Stegall, Mark D. , Hogan, William J. , Leung, Nelson

Mayo Clinic

Transplantation | October 8, 2020 | Volume: 105 | Issue: 7 | Pages: 1615-1624

10.1097/tp.0000000000003477 | PMID 33031227 Get It

Background. Experience with sequential hematopoietic stem cell transplant (HSCT) and kidney transplant (KT) is limited. Methods. We conducted a retrospective observational study of adult patients who underwent both HSCT and KT at our center, with a median follow-up of 11 y. Results. In our 54 patients cohort (94% autologous HSCT), 36 (67%) patients received HSCT first followed by KT, while 18 (33%) received KT before HSCT. In both groups, AL amyloidosis represented 50% of hematologic diagnosis. Only 4 patients expired due to hematologic disease relapse (2 patients in each group) and only 3 allografts were lost due to hematologic disease recurrence (HSCT first n = 1 and KT first n = 2). Overall 1, 5, and 10 y death-censored graft survival rates were 94%, 94%, and 94%, respectively, for the HSCT first group and 89%, 89%, and 75%, respectively, for the KT first group. Overall 1, 5, and 10 y patients survival rates were 100%, 97% and 90%, respectively, for the HSCT first group and 100%, 76%, and 63%, respectively, for the KT first group. Conclusions. Our study supports safety of sequential KT and HSCT, with improved overall patient survival compared to recipients of HSCT remaining on dialysis and good long-term kidney allograft outcome.
Month-long Respiratory Support by a Wearable Pumping Artificial Lung in an Ovine Model
Orizondo, Ryan A. , Omecinski, Katelin S. , May, Alexandra G., Dhamotharan, Vishaal , Frankowski, Brian J., Burgreen, Greg W. , Ye, Sang‐Ho , Koçyıldırım, Ergin, Sánchez, Pablo G. , D’Cunha, Jonathan, Wagner, William R. , Federspiel, William J.

Mayo Clinic

Transplantation | October 8, 2020 | Volume: 105 | Issue: 5 | Pages: 999-1007

10.1097/tp.0000000000003481 | PMID 33031226 Get It

Background. A wearable artificial lung could improve lung transplantation outcomes by easing implementation of physical rehabilitation during long-term pretransplant respiratory support. The Modular Extracorporeal Lung Assist System (ModELAS) is a compact pumping artificial lung currently under development. This study evaluated the long-term in vivo performance of the ModELAS during venovenous support in awake sheep. Feedback from early trials and computational fluid dynamic analysis guided device design optimization along the way. Methods. The ModELAS was connected to healthy sheep via a dual-lumen cannula in the jugular vein. Sheep were housed in a fixed-tether pen while wearing the device in a holster during support. Targeted blood flow rate and support duration were 2–2.5 L/min and 28–30 days, respectively. Anticoagulation was maintained via systemic heparin. Device pumping and gas exchange performance and hematologic indicators of sheep physiology were measured throughout support. Results. Computational fluid dynamic-guided design modifications successfully decreased pump thrombogenicity from initial designs. For the optimized design, 4 of 5 trials advancing past early perioperative and cannula-related complications lasted the full month of support. Blood flow rate and CO2 removal in these trials were 2.1 ± 0.3 L/min and 139 ± 15 mL/min, respectively, and were stable during support. One trial ended after 22 days of support due to intradevice thrombosis. Support was well tolerated by the sheep with no signs of hemolysis or device-related organ impairment. Conclusions. These results demonstrate the ability of the ModELAS to provide safe month-long support without consistent deterioration of pumping or gas exchange capabilities.
Utilisation of artificial intelligence for the development of an EUS-convolutional neural network model trained to enhance the diagnosis of autoimmune pancreatitis
Marya, Neil B. , Powers, Patrick, Chari, Suresh T. , Gleeson, Ferga C. , Leggett, Cadman L. , Dayyeh, Barham K. Abu , Iyer, Prasad G. , Majumder, Shounak , Pearson, Randall K., Petersen, Bret T. , Rajan, Elizabeth , Sawas, Tarek , Vege, Santhi Swaroop, Chen, Shigao , Long, Zaiyang , Hough, David M., Mara, Kristin C. , Levy, Michael J. , Abu Dayyeh, Barham K , Iyer, P G , Majumder, Shounak , Sawas, T , Vege, Santhi S, Mara, Kristin, Mara, Kristin C , Leggett, Cadman L , Chari, Suresh T , Marya, Neil B. , Chandrasekhara, Vinay , Storm, Andrew C. , Vege, Santhi Swaroop , Levy, Michael J.

Mayo Clinic

Gut | October 7, 2020 | Volume: 70 | Issue: 7 | Pages: 1335-1344

10.1136/gutjnl-2020-322821 | PMID 33028668 Get It

Objective The diagnosis of autoimmune pancreatitis (AIP) is challenging. Sonographic and cross-sectional imaging findings of AIP closely mimic pancreatic ductal adenocarcinoma (PDAC) and techniques for tissue sampling of AIP are suboptimal. These limitations often result in delayed or failed diagnosis, which negatively impact patient management and outcomes. This study aimed to create an endoscopic ultrasound (EUS)-based convolutional neural network (CNN) model trained to differentiate AIP from PDAC, chronic pancreatitis (CP) and normal pancreas (NP), with sufficient performance to analyse EUS video in real time. Design A database of still image and video data obtained from EUS examinations of cases of AIP, PDAC, CP and NP was used to develop a CNN. Occlusion heatmap analysis was used to identify sonographic features the CNN valued when differentiating AIP from PDAC. Results From 583 patients (146 AIP, 292 PDAC, 72 CP and 73 NP), a total of 1 174 461 unique EUS images were extracted. For video data, the CNN processed 955 EUS frames per second and was: 99% sensitive, 98% specific for distinguishing AIP from NP; 94% sensitive, 71% specific for distinguishing AIP from CP; 90% sensitive, 93% specific for distinguishing AIP from PDAC; and 90% sensitive, 85% specific for distinguishing AIP from all studied conditions (ie, PDAC, CP and NP). Conclusion The developed EUS-CNN model accurately differentiated AIP from PDAC and benign pancreatic conditions, thereby offering the capability of earlier and more accurate diagnosis. Use of this model offers the potential for more timely and appropriate patient care and improved outcome.
The voltage-gated proton channel Hv1 contributes to neuronal injury and motor deficits in a mouse model of spinal cord injury
Wu, Gongxiong, Mogilevsky, Rochelle , Zheng, Xin, Hu, Peiwen, Wu, Long‐Jun , Wu, Long-Jun , Murugan, Madhuvika , Zheng, Jiaying , Wu, Junfang

Mayo Clinic

No container title available | October 6, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-59578/v2 Get It

Abstract Traumatic injury to the spinal cord initiates a series of pathological cellular processes that exacerbate tissue damage at and beyond the original site of injury. This secondary damage includes oxidative stress and inflammatory cascades that can lead to further neuronal loss and motor deficits. Microglial activation is an essential component of these secondary signaling cascades. The voltage-gated proton channel, Hv1, functionally expressed in microglia has been implicated in microglia polarization and oxidative stress in ischemic stroke. Here, we investigate whether Hv1 mediates microglial/macrophage activation and aggravates secondary damage following spinal cord injury (SCI). Following contusion SCI, wild-type (WT) mice showed significant tissue damage, white matter damage and impaired motor recovery. However, mice lacking Hv1 (Hv1-/-) showed significant white matter sparing and improved motor recovery. The improved motor recovery in Hv1-/- mice was associated with decreased interleukin-1β, reactive oxygen/ nitrogen species production and reduced neuronal loss. Further, deficiency of Hv1 directly influenced microglia activation as noted by decrease in microglia numbers, soma size and reduced outward rectifier K+ current density in Hv1-/- mice compared to WT mice at 7 d following SCI. Our results therefore implicate that Hv1 may be a promising potential therapeutic target to alleviate secondary damage following SCI caused by microglia/macrophage activation.
Long‐term clinical and patient‐reported outcomes in free flap reconstruction of the weight‐bearing heel pad and non‐weight‐bearing Achilles tendon regions
Grauberger, Jennifer , Moran, Steven L. , Carlsen, Brian T. , Bakri, Karim , Grauberger, Jennifer N , Gibreel, Waleed O, Moran, Steven L , Gibreel, Waleed

Mayo Clinic

Microsurgery | October 2, 2020 | Volume: 40 | Issue: 8 | Pages: 835-845

10.1002/micr.30658 | PMID 33006778 Get It

AbstractBackgroundThe non‐weight‐bearing (NWB) Achilles tendon and weight‐bearing (WB) heel pad regions are technically challenging to reconstruct with distinct functional and aesthetic considerations that have not been previously considered in the literature. This study is the first to characterize the long‐term clinical and patient‐reported outcomes of these components to better inform patients about the postreconstruction period.MethodsA retrospective review of medical records and phone‐based survey of adult patients who underwent free flap reconstruction of the heel/ankle with 6‐month minimum clinical follow‐up was performed.ResultsForty‐three patients, with 31 (72.1%) NWB and 12 (27.9%) WB defects, treated from January 1, 2000 to February 28, 2017 were included. Muscle flaps were more common than fasciocutaneous flaps (N = 36 [83.7%] vs. 7 [16.3%]). Flap survival rate was 95.3% and limb salvage rate was 93.0% at median follow‐up of 12.0 months (interquartile range [IQR] 6.2, 25.5). Flap ulceration occurred more frequently in the WB region (41.7 vs. 6.5%, p = .0123). The survey response rate was 63.6%. The majority of patients complete daily tasks with no/little impairment (76.2%), walk half a mile or more (85.7%), returned to work (86.6%), and fit shoes “fair” or “well” (71.4%). Most patients were “very satisfied” with heel/ankle function (71.4%) and would “very likely” undergo the same procedure if needed (76.2%).ConclusionsFree flap reconstruction in both the NWB Achilles tendon and WB heel pad has excellent limb salvage and flap survival rates. Patients were satisfied with heel/ankle function, but additional counseling is recommended for variance in appearance and higher ulceration rates in WB defects.
Novel t(1;8)(p31.3;q21.3) NFIA-RUNX1T1 Translocation in an Infant Erythroblastic Sarcoma
King, Rebecca L. , Siaghani, Parwiz, Wong, Katy K., Edlefsen, Kerstin L., Shane, Lisa, Howard, Matthew T., Reichard, Kaaren K. , Mai, Ming, Viswanatha, David S., Greipp, Patricia T. , Goble, Tony A., Ruiz, Maritza E., Hara, Harneet, Greipp, Patricia T

Mayo Clinic

American Journal of Clinical Pathology | September 29, 2020 | Volume: 156 | Issue: 1 | Pages: 129-138

10.1093/ajcp/aqaa216 | PMID 33313700 Get It

Abstract Objectives Pure erythroid leukemia (PEL) is exceptionally rare in the pediatric setting. Four pediatric PEL cases with t(1;16)(p31;q24) NFIA-CBFA2T3 were reported previously. We present a case of an infant with PEL presenting with erythroblastic sarcoma and harboring a novel t(1;8)(p31.3;q21.3) NFIA-RUNX1T1 fusion detected by RNA sequencing and conventional karyotype. Methods Bone marrow (BM) and abdominal mass biopsies from the patient were evaluated with extensive immunohistochemical, flow cytometric, cytogenetic, and molecular studies. Results The patient was a female infant who presented between 2 and 5 months of age with cytopenias and an enlarging abdominal mass. Blasts in the BM and abdominal mass expressed CD71 and CD117 with focal expression of CD43, E-cadherin, epithelial membrane antigen, and hemoglobin A. They were negative for additional myeloid, lymphoid, and nonhematolymphoid markers. These findings were most consistent with PEL and erythroblastic sarcoma. RNA sequencing revealed the novel NFIA-RUNX1T1 fusion. Conclusions Along with the previously reported PELs with NFIA-CBFA2T3 fusions, we describe a subset of PELs that occur in children, that frequently display extramedullary disease, and that harbor rearrangements of NFIA with core binding factor genes. We hypothesize that, together, these cases represent a rare but distinct clinicopathologic group of pediatric PELs with recurrent genetic abnormality.
Mendelian Randomization Analysis of n-6 Polyunsaturated Fatty Acid Levels and Pancreatic Cancer Risk
Ghoneim, Dalia, Zhu, Jingjing , Murff, Harvey J. , Ye, Fei , Khankari, Nikhil K. , Haycock, Philip , Antwi, Samuel O. , Yang, Yaohua , Arslan, Alan A. , Bracci, Paige M. , Du, Mengmeng , Gallinger, Steven , Goodman, Phyllis J. , Scélo, Ghislaine , Visvanathan, Kala , Andreotti, Gabriella , Babić, Ana , Berndt, Sonja I. , Brennan, Paul , Bueno‐de‐Mesquita, Bas , Buring, Julie E. , Rabe, Kari G. , Duggal, Priya , Fuchs, Charles S. , Gaziano, J. Michael , Hackert, Thilo , Hassan, Manal M. , Helzlsouer, Kathy J. , Holly, Elizabeth A. , Hoover, Robert N. , Katske, Verena, Kurtz, Robert C. , Lee, I‐Min , Murphy, Neil , Oberg, Ann L. , Porta, Miquel , Rothman, Nathaniel , Sesso, Howard D. , Wactawski‐Wende, Jean , Wentzensen, Nicolas , Wolpin, Brian M. , Jacobs, Eric J. , Petersen, Gloria M. , Stolzenberg-Solomon, Rachel Z., Wu, Lang , Haycock, Philip , Arslan, Alan A , Canzian, Federico , Giles, Graham G , Visvanathan, Kala , Bamlet, William R , Brennan, Paul , Chaffee, Kari G. , Hackert, Thilo , Katzke, Verena , Malats, Nuria , Milne, Roger L , Oberg, Ann L , Sesso, Howard D , Wactawski-Wende, Jean , Yu, Herbert , Duell, Eric J , Amundadottir, Laufey , Klein, Alison P , Antwi, Samuel O , Murphy, Neil , Porta, Miquel , Duggal, Priya , Zheng, Wei , Long, Jirong , Setiawan, Veronica Wendy , Wilkens, Lynne R. , Freeman, Laura E. Beane , Canzian, Federico , Giles, Graham G. , Kooperberg, Charles , Marchand, Loı̈c Le , Neale, Rachel Ε. , White, Emily , Albanes, Demetrius , Amiano, Pilar , Bamlet, William R. , Brais, Lauren K , Campbell, Peter T. , Chanock, Stephen Jacob , Goggins, Michael , Malats, Núria , Milne, Roger L. , Rothman, Nathaniel , Silverman, Debra T. , Thompson, Ian M. , Wang, Xiaoliang , Yu, Kai , Zeleniuch‐Jacquotte, Anne , Duell, Eric J. , Risch, Harvey A. , Ámundadóttir, Laufey T. , Kraft, Peter , Klein, Alison P. , Shu, Xiao‐Ou , Yang, Yaohua

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | September 23, 2020 | Volume: 29 | Issue: 12 | Pages: 2735-2739

10.1158/1055-9965.epi-20-0651 | PMID 32967863 Get It

Abstract Background: Whether circulating polyunsaturated fatty acid (PUFA) levels are associated with pancreatic cancer risk is uncertain. Mendelian randomization (MR) represents a study design using genetic instruments to better characterize the relationship between exposure and outcome. Methods: We utilized data from genome-wide association studies within the Pancreatic Cancer Cohort Consortium and Pancreatic Cancer Case–Control Consortium, involving approximately 9,269 cases and 12,530 controls of European descent, to evaluate associations between pancreatic cancer risk and genetically predicted plasma n-6 PUFA levels. Conventional MR analyses were performed using individual-level and summary-level data. Results: Using genetic instruments, we did not find evidence of associations between genetically predicted plasma n-6 PUFA levels and pancreatic cancer risk [estimates per one SD increase in each PUFA-specific weighted genetic score using summary statistics: linoleic acid odds ratio (OR) = 1.00, 95% confidence interval (CI) = 0.98–1.02; arachidonic acid OR = 1.00, 95% CI = 0.99–1.01; and dihomo-gamma-linolenic acid OR = 0.95, 95% CI = 0.87–1.02]. The OR estimates remained virtually unchanged after adjustment for covariates, using individual-level data or summary statistics, or stratification by age and sex. Conclusions: Our results suggest that variations of genetically determined plasma n-6 PUFA levels are not associated with pancreatic cancer risk. Impact: These results suggest that modifying n-6 PUFA levels through food sources or supplementation may not influence risk of pancreatic cancer.
Society of Critical Care Medicine’s International Consensus Conference on Prediction and Identification of Long-Term Impairments After Critical Illness
Still, Mary, Brodsky, Martin B. , Butcher, Brad W. , Clay, Alison S. , Felt, Hali, Ferrante, Lauren E. , Hope, Aluko A. , Hopkins, Ramona O., Hosey, Megan M. , Hough, C.T., Jackson, James C. , Johnson, Annie, Khan, Babar , Lone, Nazir , MacTavish, Pamela , McPeake, Joanne , Montgomery-Yates, Ashley , Needham, Dale M. , Netzer, Giora, Skidmore, Becky , Stollings, Joanna L. , Umberger, Reba , Andrews, Adair, Iwashyna, Theodore J. , Sevin, Carla M. , Mikkelsen, Mark E. , Anderson, Brian J. , Bienvenu, O. Joseph , Brummel, Nathan E. , Haines, Kimberley , Harhay, Michael Oscar , Schorr, Christa

Mayo Clinic

Critical Care Medicine | September 18, 2020 | Volume: 48 | Issue: 11 | Pages: 1670-1679

10.1097/ccm.0000000000004586 | PMID 32947467 Get It

Background: After critical illness, new or worsening impairments in physical, cognitive, and/or mental health function are common among patients who have survived. Who should be screened for long-term impairments, what tools to use, and when remain unclear. Objectives: Provide pragmatic recommendations to clinicians caring for adult survivors of critical illness related to screening for postdischarge impairments. Participants: Thirty-one international experts in risk-stratification and assessment of survivors of critical illness, including practitioners involved in the Society of Critical Care Medicine’s Thrive Post-ICU Collaboratives, survivors of critical illness, and clinical researchers. Design: Society of Critical Care Medicine consensus conference on post-intensive care syndrome prediction and assessment, held in Dallas, in May 2019. A systematic search of PubMed and the Cochrane Library was conducted in 2018 and updated in 2019 to complete an original systematic review and to identify pre-existing systematic reviews. Meeting Outcomes: We concluded that existing tools are insufficient to reliably predict post-intensive care syndrome. We identified factors before (e.g., frailty, preexisting functional impairments), during (e.g., duration of delirium, sepsis, acute respiratory distress syndrome), and after (e.g., early symptoms of anxiety, depression, or post-traumatic stress disorder) critical illness that can be used to identify patients at high-risk for cognitive, mental health, and physical impairments after critical illness in whom screening is recommended. We recommend serial assessments, beginning within 2–4 weeks of hospital discharge, using the following screening tools: Montreal Cognitive Assessment test; Hospital Anxiety and Depression Scale; Impact of Event Scale-Revised (post-traumatic stress disorder); 6-minute walk; and/or the EuroQol-5D-5L, a health-related quality of life measure (physical function). Conclusions: Beginning with an assessment of a patient’s pre-ICU functional abilities at ICU admission, clinicians have a care coordination strategy to identify and manage impairments across the continuum. As hospital discharge approaches, clinicians should use brief, standardized assessments and compare these results to patient’s pre-ICU functional abilities (“functional reconciliation”). We recommend serial assessments for post-intensive care syndrome-related problems continue within 2–4 weeks of hospital discharge, be prioritized among high-risk patients, using the identified screening tools to prompt referrals for services and/or more detailed assessments.
Technical Note: Optimization of quantitative susceptibility mapping by streaking artifact detection
Wu, Ming‐Long, Wang, Chun‐Kun, Lin, Po‐Yu , Chao, Tzu Cheng , Wang, Chun‐Kun, Lin, Po‐Yu

Mayo Clinic

Medical Physics | September 18, 2020 | Volume: 47 | Issue: 11 | Pages: 5715-5722

10.1002/mp.14460 | PMID 32945538 Get It

PurposeIn quantitative susceptibility mapping (QSM) using magnetic resonance imaging, image reconstruction methods usually aim at suppressing streaking artifacts. In this study, a streaking detection method is proposed for evaluating and optimizing quantitative susceptibility maps.MethodsNine healthy subjects participated in this study and underwent three‐dimensional multi‐echo gradient echo scans. Regularized iterative algorithm was used for reconstruction of tissue susceptibility maps in all subjects. Streaking detection was applied to evaluate streaking artifact in tissue susceptibility maps. In addition, an optimization process for QSM reconstruction by streaking detection was applied and was compared with matching noise level method.ResultsIt is shown that the proposed streaking detection technique effectively delineates streaking artifact in tissue susceptibility maps. In QSM reconstruction, optimization by streaking detection successfully determines the regularization factor that balances between streaking artifact suppression and tissue texture preservation. ROI analyses of brain tissue susceptibility show that optimization by streaking detection achieves results in good agreement with that from matching noise level method.ConclusionsStreaking detection enables direct visualization of streaking patterns in tissue susceptibility maps. It can be applied both for evaluating QSM reconstruction quality and for comparing different reconstruction algorithms. Furthermore, streaking detection can be incorporated into an optimization process of QSM reconstruction. Therefore, we conclude that the proposed method will add value to reconstruction of QSM.
Promise and Potential Peril With Lumacaftor for the Trafficking Defective Type 2 Long-QT Syndrome-Causative Variants, p.G604S, p.N633S, and p.R685P, Using Patient-Specific Re-Engineered Cardiomyocytes
O’Hare, Bailey J. , Kim, C.S. John, Hamrick, Samantha K. , Ye, Dan , Tester, David J. , Ackerman, Michael J.

Mayo Clinic

Circulation: Genomic and Precision Medicine | September 17, 2020 | Volume: 13 | Issue: 5 | Pages: 466-475

10.1161/circgen.120.002950 | PMID 32940533 Get It

Background: The KCNH2 -encoded Kv11.1 hERG (human ether-a-go-go related gene) potassium channel is a critical regulator of cardiomyocyte action potential duration (APD). The majority of type 2 long-QT syndrome (LQT2) stems from trafficking defective KCNH2 mutations. Recently, Food and Drug Administration-approved cystic fibrosis protein trafficking chaperone, lumacaftor, has been proposed as novel therapy for LQT2. Here, we test the efficacy of lumacaftor treatment in patient-specific induced pluripotent stem cell-cardiomyocytes (iPSC-CMs) derived from 2 patients with known LQT2 trafficking defective mutations and a patient with novel KCNH2 variant, p.R685P. Methods: Patient-specific iPSC-CM models of KCNH2-G604S, KCNH2-N633S, and KCNH2-R685P were generated from 3 unrelated patients diagnosed with severe LQT2 (rate-corrected QT>500 ms). Lumacaftor efficacy was also tested by ANEPPS, FluoVolt, and ArcLight voltage dye-based APD90 measurements. Results: All 3 mutations were hERG trafficking defective in iPSC-CMs. While lumacaftor treatment failed to rescue the hERG trafficking defect in TSA201 cells, lumacaftor rescued channel trafficking for all mutations in the iPSC-CM model. All 3 mutations conferred a prolonged APD90 compared with control. While lumacaftor treatment rescued the phenotype of KCNH2-N633S and KCNH2-R685P, lumacaftor paradoxically prolonged the APD90 in KCNH2-G604S iPSC-CMs. Lumacaftor-mediated APD90 rescue was affected by rapidly activating delayed rectifier K+ current blocker consistent with the increase of rapidly activating delayed rectifier K+ current by lumacaftor is the underlying mechanism of the LQT2 rescue. Conclusions: While lumacaftor is an effective hERG channel trafficking chaperone and may be therapeutic for LQT2, we urge caution. Without understanding the functionality of the mutant channel to be rescued, lumacaftor therapy could be harmful.